<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-056101</identifier>
<setSpec>0212-7199</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">The antiphospholipid sindrome, an update</dc:title>
<dc:description xml:lang="en">The antiphospholipid syndrome is an antibody mediated hypercoagulable        state characterized by recurrent venous and arterial thromboembolic        events. Several studies have determined that the frequency of antiphospholipid        syndrome in patients presenting with a venous thromboembolic        event is between 4% and 14%. Classical criteria include the presence of        anticardiolipin antibody or lupus anticoagulant with typical complications        of thrombosis or pregnancy loss. Other common associated manifestations        include livedo reticularis, thrombocytopenia, valvular heart        disease, and nephropathy with renal insufficiency, hypertension and proteinuria.        Because of the high risk for recurrent thromboembolism in these        patients, current recommendations suggest a longer, potentially lifelong,        course of antithrombotic therapy following an initial event. For an        initial venous thromboembolic event, a target INR of 2.0 to 3.0 is supported        by two prospective, randomized clinical trials. In contrast, relatively        limited data exist for an initial arterial thromboembolic event in patients        who have the antiphospholipid syndrome, and therapeutic recommendations        range from aspirin to warfarin with a high target INR. Recurrent        thromboembolic events can be extremely difficult to treat, and some        patients may benefit from the addition of immunosuppressive therapies.        It is very important to evaluate in this setting additional, coincident        prothrombotic risk factors</dc:description>
<dc:creator>Pérez Paredes, G</dc:creator>
<dc:creator>Inglada Galiana, L</dc:creator>
<dc:creator>Alonso Santor, J. E</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El síndrome antifosfolípido afecta al campo de la practica médica de        varias especialidades; es un estado de hipercoagulabilidad mediado por        anticuerpos caracterizado por episodios de tromboembolismos arteriales        y venosos, su frecuencia en pacientes que sufren un episodio de tromboembolismo        venoso oscila entre un 14 a un 45%. Los criterios clásicos        incluyen la presencia de anticuerpos anticardiolipina o anticoagulante        lúpico, las complicaciones trombóticas y los abortos espontáneos. Otras        manifestaciones frecuentes incluyen la livedo reticularis, trombocitopenia,        enfermedad valvular cardiaca, nefropatía con insuficiencia renal,        hipertensión y proteinuria. Se aconseja un tratamiento anticoagulante        prolongado después del primer episodio trombótico, en caso de que ocurra        un tromboembolismo venoso, se recomienda mantener el INR entre 2        y 3, por el contrario existen menos datos referentes al tratamiento en caso        de que la afectación sea arterial en cuyo caso se aconseja el uso de aspirina        y/o warfarina manteniendo niveles mas altos de INR. En caso que se        presenten episodios tromboembólicos recurrentes de tromboembolismo        algunos pacientes se pueden beneficiar del tratamiento con inmunosupresores,        y en cualquier caso se debe de realizar un estudio que valore la        existencia de factores protrombóticos</dc:description>
<dc:source>An Med Interna;24(5): 242-248, mayo 2007. tab</dc:source>
<dc:identifier>ibc-056101</dc:identifier>
<dc:title xml:lang="es">Síndrome antifosfolípido, estado actual</dc:title>
<dc:subject>^d24529</dc:subject>
<dc:subject>^d25^s22027</dc:subject>
<dc:subject>^d33361^s22027</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d30257^s22016</dc:subject>
<dc:subject>^d30257^s22038</dc:subject>
<dc:subject>^d30834^s22038</dc:subject>
<dc:subject>^d30257^s22057</dc:subject>
<dc:subject>^d30833^s22038</dc:subject>
<dc:subject>^d30257^s22012</dc:subject>
<dc:type>article</dc:type>
<dc:date>200705</dc:date>
</metadata>
</record>
</ibecs-document>
